1. Home
  2. AGEN vs KF Comparison

AGEN vs KF Comparison

Compare AGEN & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.46

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

HOLD

Current Price

$75.20

Market Cap

268.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
KF
Founded
1994
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
268.5M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
KF
Price
$3.46
$75.20
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
744.4K
22.3K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
1.02
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.32
N/A
Revenue Growth
89.95
N/A
52 Week Low
$2.71
$22.28
52 Week High
$7.34
$74.99

Technical Indicators

Market Signals
Indicator
AGEN
KF
Relative Strength Index (RSI) 48.00 67.23
Support Level $2.93 $28.52
Resistance Level $4.72 N/A
Average True Range (ATR) 0.24 2.52
MACD 0.01 0.32
Stochastic Oscillator 68.46 91.92

Price Performance

Historical Comparison
AGEN
KF

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.

Share on Social Networks: